Evogene's Latest Financial Results Showcase Significant Advances in Drug Discovery Programs
Evogene's Financial Results and Strategic Advancements
On November 19, 2026, Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) released its financial outcomes for the third quarter and the first nine months of the year. The Israeli biotechnology firm is well-known for utilizing its proprietary ChemPass AI™, an innovative AI-driven platform dedicated to the development of small molecules for pharmaceutical and agricultural applications.
Financial Overview
As of September 30, 2026, the company's total cash and cash equivalents stood at approximately $9.2 million. Evogene's consolidated cash usage during the third quarter totaled around $2.4 million. Revenue for the initial nine months of 2026 was reported at approximately $0.8 million, a decrease from the $3.2 million generated during the same period in 2025. This decline is primarily attributed to reduced income from Casterra, a subsidiary, which had significant seed sales in 2025 that were not replicated in 2026. During the third quarter, revenues were recorded at $0.1 million, down from $0.3 million in the previous year, significantly affected by the termination of a license agreement with Bayer earlier in May 2026.
Development Initiatives
In line with its business strategy, Evogene has been diligently advancing two internal programs that have the potential to strengthen its proprietary asset pipeline. The first initiative targets acute graft-versus-host disease (aGVHD), which presents a significant unmet medical need. Utilizing ChemPass AI™, Evogene has generated various small molecule candidates demonstrating compelling biological activity at nanomolar concentrations, along with favorable preliminary absorption, distribution, metabolism, excretion (ADME), and toxicity profiles. The next goal is to fine-tune these promising molecules and facilitate the transition toward IND-enabling studies.
The second program, run through Evogene’s subsidiary AgPlenus, centers on discovering new fungicides that employ innovative mechanisms of action to combat Septoria tritici blotch, a major challenge in wheat cultivation attributed to rising resistance against existing treatments. The ChemPass AI for Ag™ platform has already identified compounds that notably reduce disease severity by up to 75%, compared to untreated controls, showcasing activity against resistant strains and other fungal threats.
Research and Development Expenses
During the first nine months of 2026, combined research and development expenses reached approximately $4.5 million, a slight decrease from about $4.6 million during the same timeframe in 2025. The R&D spending for the third quarter increased to approximately $1.5 million, compared to $1.1 million in Q3 2025. This uptick is mainly due to the recognition of non-refundable grants and adjustments connected to government grants.
Sales and Marketing Outlook
Sales and marketing expenditures for the nine months of 2026 totaled roughly $0.9 million, down from $1.1 million in 2025. For Q3 alone, these costs came to $0.2 million, a reduction from $0.4 million in the prior year. The decrease reflects scaled-back spending within both Casterra and AgPlenus.
Administrative and Financing Costs
General and administrative expenses decreased to about $3.1 million from $3.2 million in the previous year. However, specific non-recurring transaction and legal costs related to governance and shareholders led to higher expenses, totaling approximately $0.7 million in total during both periods.
In terms of financing, Evogene faced a net financing expense of roughly $1.6 million for the first nine months of 2026, compared to a financing income of $0.9 million in the same period last year. This shift is linked to various accounting treatments and the revaluation of warrants associated with previous financing activities.
The net loss for the year-to-date period reached approximately $10.5 million, significantly up from $2.5 million in 2025, primarily driven by reduced revenues and increased financing costs. Notably, Q3 saw a net loss of $2.9 million versus a net income of about $5.2 million in 2025, attributed to gains realized from prior transactions.
Conclusion
Evogene’s recent financial report suggests a focused strategy on advancing its AI-driven drug discovery capabilities and agricultural solutions amid a challenging revenue landscape. The advances in the aGVHD drug discovery program and AgPlenus’ fungicidal developments signal ongoing commitment to meeting critical unmet needs in both pharma and agri-chemical sectors while building shareholder value in the long term.
For more information regarding Evogene and AgPlenus, please visit their respective websites.